Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot
1. Valneva's chikungunya vaccine shows 98.3% sero-response in adolescents one year post-vaccination. 2. The promising data supports label extension filings in the U.S., Europe, and Canada. 3. License support expected in Brazil for first approval in endemic populations. 4. Single-dose vaccine is well tolerated; independent board found no safety issues.